[HTML] from ascopubs.orgEA Perez, EH Romond, VJ Suman… - Journal of Clinical …, 2011 - jco.ascopubs.org Purpose Trastuzumab is a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). The clinical benefits of adjuvant trastuzumab have been demonstrated in interim analyses of four large trials. Initial data of the combined analysis of the North ...
F Li… - Science, 2011 - sciencemag.org CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, is expressed on antigen-presenting cells (APCs) and is essential for immune activation. Although agonistic CD40 antibodies have been developed for immunotherapy, their clinical efficacy has been ... Cited by 1
[HTML] from thelancet.comL Gianni, U Dafni, RD Gelber, E Azambuja… - The Lancet …, 2011 - Elsevier The HERA trial is an international, multicentre, randomised, open-label, phase 3 trial comparing treatment with trastuzumab for 1 and 2 years with observation after standard neoadjuvant, adjuvant chemotherapy, or both in patients with HER2-positive early breast cancer. The primary ... Cited by 7 - Related articles - All 7 versions
G Tang, S Shak, S Paik, SJ Anderson… - Breast cancer research …, 2011 - Springer Abstract The Oncotype DX ® Recurrence Score® (RS) is a validated genomic predictor of outcome and response to adjuvant chemotherapy in ER-positive breast cancer. Adjuvant! was developed using SEER registry data and results from the Early Breast Cancer Clinical Trialists' ... Cited by 2 - Related articles - All 4 versions
[HTML] from oxfordjournals.orgFA Sinicrope, NR Foster… - Journal of the …, 2011 - jnci.oxfordjournals.org Methods We included stage II and III colon carcinoma patients (n = 2141) who were treated in randomized trials of 5-FU-based adjuvant therapy. Tumors were analyzed for microsatellite instability by polymerase chain reaction and/or for MMR protein expression by ... Cited by 1 - Related articles - All 5 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
